Patient P-03379
Therapy response
Declining
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Deteriorating
Nutritional resilience
Unstable
Discontinuation risk
55%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S12
- Day 10 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 102 GI-04 recommended — GI Support Protocol GI-04
- Day 103 Patient accepted — Started GI-04 in the companion
- Day 111 GI symptom burden −10% vs expected — GI Support Protocol GI-04
- Day 117 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 10.
Primary contributors, last 14 days
- Toxicity+14
- Treatment adherence-8
- GI instability+7
- Inflammatory activity+7
- Nutritional resilience-6
What helped?
- GI Support Protocol GI-04Day 102Result: symptom burden −10%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
70%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 5 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 42
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 42/100
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 54
- Autonomic recovery ↓25
- WearableResting HR 80 bpm
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.4 · butyrate capacity 42/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 40 ms
- Sleep
- 6.8 h
- Steps
- 7,187
- Resting HR
- 79 bpm
Daily log: GI score 59, nutritional resilience 42, adherence 84.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03120 | 46% | S14 | — | — | 61 |
| P-03285 | 45% | S04 | — | — | 54 |
| P-03451 | 44% | S08 | — | — | 62 |
| P-03221 | 42% | S06 | GI-04 | no change | 64 |
| P-03292 | 42% | S14 | — | — | 62 |
| P-03031 | 41% | S16 | CR-01 | improved | 49 |
| P-03004 | 40% | S03 | — | — | 56 |
| P-03021 | 40% | S15 | — | — | 57 |
| P-03218 | 39% | S20 | — | — | 56 |
| P-03225 | 39% | S19 | GI-04 | improved | 50 |
| P-03382 | 39% | S01 | GI-04 | improved | 56 |
| P-03378 | 38% | S10 | — | — | 59 |